A phase Ib extension study of cancer sternness inhibitor BB608 (napabucasin) in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer.

被引：6
|
作者：
El-Rayes, Bassel F.
Shanda, Safi
Starodub, Alexander
O'Neil, Bert H.
Hanna, Wahid Tewfik
Shaib, Walid Labib
Oh, Cindy
Li, Wei
Li, Youzhi
Borodyansky, Laura
Li, Chiang
Bekaii-Saab, Tanios S.
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Indiana Univ, Indianapolis, IN 46204 USA
[3] Indiana Univ, Hlth Goshen Ctr Canc Care, Bloomington, IN 47405 USA
[4] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[5] Univ Tennessee, Med Ctr, Knoxville, TN USA
[6] Boston Biomed Inc, Boston, MA USA
[7] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_supp1.4128
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4128
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients.
    Barrera, Ivan
    Filimon, Sabin Dragos
    Meng, Jassy
    Kavan, Tomas
    Rho, Young Soo
    Batist, Gerald
    Kavan, Petr
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [42] A Phase I study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastasized pancreatic cancer
    Lee, K.
    Molenaar, R. J.
    Klaassen, R.
    Bijlsma, M. F.
    Weterman, M. J.
    Richel, D. J.
    Wymenga, M.
    van Laarhoven, H. W. M.
    Wilmink, J. W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] A nomogram to predict neutropenia in metastatic pancreatic cancer patients treated with gemcitabine/nab-paclitaxel
    Morelli, C.
    Formica, V.
    Nardecchia, A.
    Lucchetti, J.
    Tisone, G.
    Anselmo, A.
    Blanco, C. Del Vecchio
    Benassi, M.
    Palmieri, G.
    Argiro, R.
    Roselli, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
    Giandomenico Roviello
    Monica Ramello
    Martina Catalano
    Alberto D’Angelo
    Raffaele Conca
    Silvia Gasperoni
    Lorenzo Dreoni
    Roberto Petrioli
    Anna Ianza
    Stefania Nobili
    Michele Aieta
    Enrico Mini
    Scientific Reports, 10
  • [45] A phase IB study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: An Academic GI Cancer Consortium (AGICC) study
    Leichman, Lawrence P.
    O'Neil, Bert H.
    Berlin, Jordan
    Weekes, Colin D.
    Ames, Patricia
    McKinley, Marti
    Davies, Angela M.
    Cohen, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer
    Kawaida, Hiromichi
    Kono, Hiroshi
    Amemiya, Hidetake
    Saitou, Ryou
    Yamamoto, Atsushi
    Hosomura, Naohiro
    Watanabe, Mitsuaki
    Kimura, Ayako
    Furuya, Shinji
    Shimizu, Hiroki
    Akaike, Hidenori
    Kawaguchi, Yoshihiko
    Sudo, Makoto
    Itakura, Jun
    Hayakawa, Hiroshi
    Shindo, Hiroko
    Takahashi, Ei
    Takano, Shinichi
    Fukasawa, Mitsuharu
    Ichikawa, Shintaro
    Fujii, Hideki
    Ichikawa, Daisuke
    ANTICANCER RESEARCH, 2018, 38 (11) : 6537 - 6542
  • [47] Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
    Roviello, Giandomenico
    Ramello, Monica
    Catalano, Martina
    D'Angelo, Alberto
    Conca, Raffaele
    Gasperoni, Silvia
    Dreoni, Lorenzo
    Petrioli, Roberto
    Ianza, Anna
    Nobili, Stefania
    Aieta, Michele
    Mini, Enrico
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [48] Clinical and translational results of a phase I study, tocilizumab plus gemcitabine/nab-paclitaxel in patient with gemcitabine/nab-paclitaxel-refractory metastatic pancreatic cancer
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Aoki, Kazunori
    Yamaguchi, Kyoko
    Sawada, Noriaki
    Fujii, Etsuko
    Nishidate, Masanobu
    Fujitomo, Takashi
    Mizuno, Hideaki
    Kayukawa, Yoko
    Kato, Atsuhiko
    Makikawa, Mayu
    Imaoka, Hiroshi
    Sasaki, Mitsuhito
    Watanabe, Kazuo
    Tsunoda, Hiroyuki
    Terao, Kimio
    Ochiai, Atsushi
    CANCER RESEARCH, 2022, 82 (12)
  • [49] A phase Ib dose escalation study of vantictumab (VAN) in combination with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer
    Davis, S. Lindsey
    Cardin, Dana Backlund
    Shahda, Safi
    Lenz, Heinz-Josef
    Dotan, Efrat
    O'Neil, Bert
    Kapoun, Ann M.
    Stagg, Robert J.
    Berlin, Jordan
    Messersmith, Wells A.
    Cohen, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [50] Napabucasin plus nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study
    Bekaii-Saab, T.
    Okusaka, T.
    Goldstein, D.
    Oh, D-Y.
    Ueno, M.
    Ioka, T.
    Fang, W.
    Anderson, E. C.
    Noel, M. S.
    Reni, M.
    Choi, H. J.
    Goldberg, J.
    Oh, S. C.
    Li, C-P.
    Tabernero, J.
    Li, J.
    Foos, E.
    Oh, C.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S1084 - S1085
12345